NO20073429L - Anvendelse av et antistoff mot interleukin-6-reseptor for fremstilling av et farmasoytisk preparat - Google Patents

Anvendelse av et antistoff mot interleukin-6-reseptor for fremstilling av et farmasoytisk preparat

Info

Publication number
NO20073429L
NO20073429L NO20073429A NO20073429A NO20073429L NO 20073429 L NO20073429 L NO 20073429L NO 20073429 A NO20073429 A NO 20073429A NO 20073429 A NO20073429 A NO 20073429A NO 20073429 L NO20073429 L NO 20073429L
Authority
NO
Norway
Prior art keywords
receptor
preparation
pharmaceutical composition
antibody against
against interleukin
Prior art date
Application number
NO20073429A
Other languages
English (en)
Other versions
NO331944B1 (no
Inventor
Tadamitsu Kishimoto
Asao Katsume
Hiroyuki Saito
Original Assignee
Tadamitsu Kishimoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17300476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073429(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20073429L publication Critical patent/NO20073429L/no
Application filed by Tadamitsu Kishimoto filed Critical Tadamitsu Kishimoto
Publication of NO331944B1 publication Critical patent/NO331944B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)

Abstract

SAMMENDRAG Det beskrives anvendelse av et antistoff mot interleukin-6-reseptor, for fremstilling av et farmasøytisk preparat for forhindring eller behandling av sykdom forårsaket av interleukin-6 produksjon. ?? ?? ?? ?? 1
NO20073429A 1994-10-21 2007-07-05 Antistoff mot interleukin-6-reseptor for behandling av sykdom. NO331944B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25701094 1994-10-21
PCT/JP1995/002169 WO1996012503A1 (fr) 1994-10-21 1995-10-20 Remede contre des maladies provoquees par la production d'il-6

Publications (2)

Publication Number Publication Date
NO20073429L true NO20073429L (no) 1997-06-18
NO331944B1 NO331944B1 (no) 2012-05-07

Family

ID=17300476

Family Applications (6)

Application Number Title Priority Date Filing Date
NO19971816A NO324046B1 (no) 1994-10-21 1997-04-18 Anvendelse av et antistoff mot interleukin-6-reseptor.
NO20073430A NO330582B1 (no) 1994-10-21 2007-07-05 Anvendelse av et antistoff mot interleukin-6-reseptor som blokkerer signal-transduksjonen til IL-6 for fremstilling av et farmasoytisk preparat for behandling av nefritt.
NO20073427A NO330615B1 (no) 1994-10-21 2007-07-05 Anvendelse av et antistoff mot IL-6-reseptor for fremstilling av et farmasoytisk preparat for behandling av kakeksi.
NO20073432A NO330589B1 (no) 1994-10-21 2007-07-05 Anvendelse av et antistoff mot interleukin-6-reseptor som blokkerer IL-6 signal-transduksjon ved a inhibere bindingen av IL-6 til IL-6-reseptoren for fremstilling av et farmasoytisk preparat.
NO20073431A NO330588B1 (no) 1994-10-21 2007-07-05 Anvendelse av et antistoff mot IL-6-reseptor som blokkerer signal-transduksjonen til IL-6 for fremstilling av et farmasoytisk preparat for behandling av anemi.
NO20073429A NO331944B1 (no) 1994-10-21 2007-07-05 Antistoff mot interleukin-6-reseptor for behandling av sykdom.

Family Applications Before (5)

Application Number Title Priority Date Filing Date
NO19971816A NO324046B1 (no) 1994-10-21 1997-04-18 Anvendelse av et antistoff mot interleukin-6-reseptor.
NO20073430A NO330582B1 (no) 1994-10-21 2007-07-05 Anvendelse av et antistoff mot interleukin-6-reseptor som blokkerer signal-transduksjonen til IL-6 for fremstilling av et farmasoytisk preparat for behandling av nefritt.
NO20073427A NO330615B1 (no) 1994-10-21 2007-07-05 Anvendelse av et antistoff mot IL-6-reseptor for fremstilling av et farmasoytisk preparat for behandling av kakeksi.
NO20073432A NO330589B1 (no) 1994-10-21 2007-07-05 Anvendelse av et antistoff mot interleukin-6-reseptor som blokkerer IL-6 signal-transduksjon ved a inhibere bindingen av IL-6 til IL-6-reseptoren for fremstilling av et farmasoytisk preparat.
NO20073431A NO330588B1 (no) 1994-10-21 2007-07-05 Anvendelse av et antistoff mot IL-6-reseptor som blokkerer signal-transduksjonen til IL-6 for fremstilling av et farmasoytisk preparat for behandling av anemi.

Country Status (13)

Country Link
US (1) US20070036785A1 (no)
EP (3) EP0791359A4 (no)
JP (1) JP4896093B2 (no)
CN (4) CN101011574B (no)
CA (1) CA2203182C (no)
CZ (3) CZ298790B6 (no)
FI (3) FI121455B (no)
HK (1) HK1067062A1 (no)
HU (2) HU227708B1 (no)
NO (6) NO324046B1 (no)
PL (1) PL182089B1 (no)
RU (1) RU2147442C1 (no)
WO (1) WO1996012503A1 (no)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
WO1999008707A1 (fr) 1997-08-15 1999-02-25 Chugai Seiyaku Kabushiki Kaisha Preventifs et/ou medicaments contre le lupus erythemateux systemique, contenant un anticorps anti-recepteur d'il-6 comme ingredient actif
CN100374159C (zh) 1998-03-17 2008-03-12 中外制药株式会社 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
ES2276525T3 (es) 1998-08-24 2007-06-16 Chugai Seiyaku Kabushiki Kaisha Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo.
DE19948126A1 (de) * 1999-10-06 2001-04-12 Max Delbrueck Centrum Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock
CN1259973C (zh) 2000-10-25 2006-06-21 中外制药株式会社 含有il－6拮抗剂作为有效成分的牛皮癣的预防或治疗剂
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
CA2489208C (en) * 2003-02-24 2012-11-06 Morinaga Milk Industry Co., Ltd. Interleukin-6 suppressive agent
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
NZ546557A (en) 2003-10-17 2010-01-29 Chugai Pharmaceutical Co Ltd Therapeutic agent for mesothelioma comprising interleukin-6
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
US8398980B2 (en) * 2004-03-24 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleuken-6 receptor
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
ES2827247T3 (es) * 2005-06-21 2021-05-20 Xoma Us Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
WO2007043641A1 (ja) 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
BRPI0617664B8 (pt) 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
CN101495146B (zh) 2006-04-07 2012-10-17 国立大学法人大阪大学 肌肉再生促进剂
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
MX2008014804A (es) 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
CN101528778A (zh) * 2006-08-18 2009-09-09 埃博灵克斯股份有限公司 用于治疗与il-6-介导的信号传导相关的疾病和病症的针对il-6r的氨基酸序列以及包括其的多肽
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
TWI438208B (zh) 2007-01-23 2014-05-21 Chugai Pharmaceutical Co Ltd 抑制慢性排斥反應之藥劑
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
MX343879B (es) * 2007-05-21 2016-11-25 Alderbio Holdings Llc Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados.
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
PL2164514T3 (pl) 2007-05-21 2017-08-31 Alderbio Holdings Llc Przeciwciała przeciwko IL-6 i ich zastosowanie
PH12018501459A1 (en) 2007-09-26 2019-11-11 Chugai Pharmaceutical Co Ltd Modified antibody constant region
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
CL2008002885A1 (es) 2007-09-26 2010-07-02 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende
EP2236604B1 (en) 2007-12-05 2016-07-06 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
ES2564635T3 (es) 2008-05-13 2016-03-28 Novimmune Sa Anticuerpos anti-IL-6/IL-6R y métodos de uso de los mismos
KR101665729B1 (ko) * 2008-06-05 2016-10-12 국립연구개발법인 고쿠리츠간켄큐센터 신경침윤 억제제
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
KR101314880B1 (ko) * 2009-03-19 2013-10-04 추가이 세이야쿠 가부시키가이샤 관절류머티즘 치료제
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
JP5647222B2 (ja) 2009-04-10 2014-12-24 アブリンクス エン．ヴェー． Ｉｌ−６ｒ関連疾患及び障害の治療のためのｉｌ−６ｒに指向性を有する改善されたアミノ酸配列及びこれを含むポリペプチド
AR076875A1 (es) 2009-05-15 2011-07-13 Chugai Pharmaceutical Co Ltd Anticuerpo contra receptor de la tirosina quinasa (anti-axl)
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
DK2493922T3 (en) 2009-10-26 2017-04-24 Hoffmann La Roche Process for preparing a glycosylated immunoglobulin
KR20120118088A (ko) 2009-11-24 2012-10-25 앨더바이오 홀딩스 엘엘씨 Ⅰｌ-6에 대한 항체 및 이들의 용도
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
DK2578231T3 (da) * 2010-05-28 2022-12-12 Chugai Pharmaceutical Co Ltd Antitumor-t-celle-reaktionsforstærker
CN103476793A (zh) 2010-11-08 2013-12-25 基因技术公司 皮下施用的抗-il-6受体抗体
EP2644698B1 (en) 2010-11-17 2018-01-03 Chugai Seiyaku Kabushiki Kaisha Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
AU2011332817A1 (en) 2010-11-23 2013-06-13 Alder Biopharmaceuticals, Inc. Anti-IL-6 antibodies for the treatment of anemia
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
BR112013021526B1 (pt) 2011-02-25 2021-09-21 Chugai Seiyaku Kabushiki Kaisha Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EP2747782B1 (en) 2011-09-23 2018-01-17 Ablynx NV Prolonged inhibition of interleukin-6 mediated signaling
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
EP2818478B1 (en) 2011-10-28 2017-02-01 Regeneron Pharmaceuticals, Inc. Humanized IL-6 and IL-6 receptor
EP2878305B1 (en) 2012-05-21 2017-07-19 Korea Research Institute of Bioscience and Biotechnology Pharmaceutical composition for use in preventing or treating stat3-mediated disease, comprising salvia plebeia r. br. extract or fraction thereof as active ingredient composition
WO2014042251A1 (ja) * 2012-09-13 2014-03-20 中外製薬株式会社 遺伝子ノックイン非ヒト動物
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
RU2758952C1 (ru) 2013-09-27 2021-11-03 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016062766A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
JP6227191B1 (ja) 2014-12-19 2017-11-08 中外製薬株式会社 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
LT3233921T (lt) 2014-12-19 2021-12-10 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antikūnai ir panaudojimo būdai
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
TWI805046B (zh) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
PL3299810T3 (pl) 2015-05-19 2021-12-13 National Center Of Neurology And Psychiatry Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm)
WO2016195088A1 (ja) 2015-06-04 2016-12-08 国立研究開発法人 国立精神・神経医療研究センター Ｉｌ－６阻害剤を有効成分とする精神疾患治療剤
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
KR20180091918A (ko) 2015-12-28 2018-08-16 추가이 세이야쿠 가부시키가이샤 Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
CA3016424A1 (en) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3574010A4 (en) 2017-01-30 2020-12-16 Chugai Seiyaku Kabushiki Kaisha ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE
US11033496B2 (en) 2017-03-17 2021-06-15 The Regents Of The University Of Michigan Nanoparticles for delivery of chemopreventive agents
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
KR20200074160A (ko) 2017-10-20 2020-06-24 가꼬우호우징 효고 이카다이가쿠 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
SG11202009010RA (en) 2018-03-15 2020-10-29 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
US11498969B2 (en) 2019-01-31 2022-11-15 Sanofi Biotechnology Compositions and methods for treating juvenile idiopathic arthritis
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
CN117247451B (zh) * 2023-11-17 2024-02-09 中国人民解放军军事科学院军事医学研究院 一种针对人白介素6蛋白的单域抗体及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
SG42954A1 (en) * 1989-07-20 1997-10-17 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
JPH03155795A (ja) * 1989-11-13 1991-07-03 Chuzo Kishimoto マウス・インターロイキン―６レセプター蛋白質
JP3045172B2 (ja) * 1990-05-19 2000-05-29 岸本 忠三 Ｉｌ―６レセプターを利用したヒトｉｌ―６の化学的測定法及びそのためのキット
JP3212597B2 (ja) * 1990-08-01 2001-09-25 忠三 岸本 ヒトｉｌ―６レセプターの免疫化学的測定法及び測定用キット
JPH04187645A (ja) * 1990-11-22 1992-07-06 Chuzo Kishimoto インターロイキン―６作用抑制剤
WO1992019759A1 (en) * 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
JPH05227970A (ja) * 1992-02-19 1993-09-07 Chugai Pharmaceut Co Ltd ヒトインターロイキン−６受容体に対する再構成ヒト抗体
JP3258348B2 (ja) * 1991-08-02 2002-02-18 東ソー株式会社 Ｈｉｖ感染阻害剤
FR2694767B1 (fr) * 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
EP0672118B1 (en) * 1992-08-21 2002-03-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES A novel b-lymphoma cell line and antigen
JP3525221B2 (ja) * 1993-02-17 2004-05-10 味の素株式会社 免疫抑制剤
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
ES2264135T3 (es) * 1995-02-13 2006-12-16 Chugai Seiyaku Kabushiki Kaisha Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6.
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
CN100374159C (zh) * 1998-03-17 2008-03-12 中外制药株式会社 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
AU2000279625A1 (en) * 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
KR100592007B1 (ko) * 2002-04-12 2006-06-21 화이자 인코포레이티드 Ｉｌ-６ 관련 질환 치료에서의 ｅｐ４ 수용체 리간드의용도
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases

Also Published As

Publication number Publication date
FI122406B (fi) 2012-01-13
CN1306963C (zh) 2007-03-28
RU2147442C1 (ru) 2000-04-20
CZ298325B6 (cs) 2007-08-29
NO330589B1 (no) 2011-05-23
NO330615B1 (no) 2011-05-30
CZ298790B6 (cs) 2008-01-30
EP1884524A2 (en) 2008-02-06
AU3709995A (en) 1996-05-15
CA2203182C (en) 2009-11-24
CN101011574A (zh) 2007-08-08
HU0304064D0 (en) 2004-03-01
CZ296979B6 (cs) 2006-08-16
NO330588B1 (no) 2011-05-23
EP1884524A3 (en) 2008-06-25
NO331944B1 (no) 2012-05-07
WO1996012503A1 (fr) 1996-05-02
NO20073432L (no) 1997-06-18
AU689657B2 (en) 1998-04-02
FI122970B (fi) 2012-09-14
EP0791359A1 (en) 1997-08-27
FI121455B (fi) 2010-11-30
HK1067062A1 (en) 2005-04-01
CN101011574B (zh) 2012-10-03
EP2319535A3 (en) 2011-08-31
EP0791359A4 (en) 2002-09-11
NO20073427L (no) 1997-06-18
US20070036785A1 (en) 2007-02-15
NO971816L (no) 1997-06-18
PL319785A1 (en) 1997-08-18
PL182089B1 (en) 2001-11-30
NO20073431L (no) 1997-06-18
HUT77035A (hu) 1998-03-02
NO324046B1 (no) 2007-08-06
JP2008297315A (ja) 2008-12-11
CN1535728A (zh) 2004-10-13
CN1164194A (zh) 1997-11-05
HU225392B1 (en) 2006-11-28
CA2203182A1 (en) 1996-05-02
JP4896093B2 (ja) 2012-03-14
FI20115753A (fi) 2011-07-15
EP2319535A2 (en) 2011-05-11
FI20105844A (fi) 2010-08-11
HU227708B1 (en) 2011-12-28
NO20073430L (no) 1997-06-18
NO971816D0 (no) 1997-04-18
CZ118997A3 (en) 1997-09-17
FI971669A0 (fi) 1997-04-18
CN100350973C (zh) 2007-11-28
NO330582B1 (no) 2011-05-16
FI971669A (fi) 1997-06-17
CN101829325A (zh) 2010-09-15

Similar Documents

Publication Publication Date Title
NO20073429L (no) Anvendelse av et antistoff mot interleukin-6-reseptor for fremstilling av et farmasoytisk preparat
BR9814393A (pt) Micropartìculas e uso terapêutico ou diagnóstico delas
FI972945A (fi) Antigeenien antamiseen soveltuvia koostumuksia
NO174239C (no) Fremgangsmåte for fremstilling av et oralt, farmasöytisk preparat
FI890282A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 23,24-didehydro-25-hydroksikalsiferolijohdannaisten valmistamiseksi
DE58906926D1 (de) Neue Arzneimittelformulierung sowie Verfahren zu deren Herstellung.
ES2013067A6 (es) Un procedimiento para producir un derivado de piperazina.
MY117090A (en) Substituted benzamidines, their preparation and their use as pharmaceutical compounds
MX7550E (es) Procedimiento enzimatico para la preparacion de acetaldheido a partir de etanol
NO954952D0 (no) Fremgangsmåte for fremstilling av en oral fast-stoff doseringsform som inneholder diklofenac
IT8219482A0 (it) Composizione farmaceutica per la cura di affezioni della cavita'orale.
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
FR2507605B1 (fr) Procede de preparation d'esters d'acides apovincaminiques, esters ainsi obtenus et compositions pharmaceutiques preparees avec ces esters
HUP9801686A2 (hu) Amino-tetralin-származék alkalmazása kardiovaszkuláris megbetegedések terápiájában használható gyógyszer előállítására
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
NO871190D0 (no) Fremgangsmaate for fremstilling av farmakologisk aktive substituerte anilider.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
NO883986L (no) Fremgangsmaate for fremstilling av n-(substituert alkyliden)-1,2,3,4-tetrahydro-9-akridinaminer og anvendelse derav som medikamenter.
NO891574L (no) Fremgangsmaate for fremstilling av farmasoeytisk anvendbareforbindelser.
DE69614552T2 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
DZ1655A1 (fr) Dérivés de la benzofuranylimidazole ainsi que leurprocédé de préparation.
ES2062313T3 (es) 13-bromo- y 13,14-dibromo-ergolinas, a su preparacion y a su utilizacion en medicamentos.
ATE74505T1 (de) Schmerzpraeparat.
ES2032573T3 (es) Procedimiento de preparacion de derivados de 4,4-dimetil-tetrahidropir-2-ona.
IT1227056B (it) Composto terapeuticamente utile, procedimento per la sua preparazione e relative composizioni farmaceutiche.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees